Has David Frank, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,252 in general payments to David Frank, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Frank, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Frank, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Frank, MD

Medical Oncology · Atlanta, GANPI 1457328957

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,832 of the $2,252 with a category attached, or 81.3%. Every reported general payment came from a single manufacturer, F. Hoffmann-la Roche AG. That places this record below the midpoint for medical oncology clinicians in GA, where the typical reported total is $5,509.

$2,252in general payments, 2019–2025

Across 5 payments — averaging $450.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

F. Hoffmann-la Roche AG$2K

$361,306in research payments, 2019–2025

Across 3 payments — averaging $120,435 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$361K

What the payments were for

Travel & lodging$1,83281%
Food & beverage$42019%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
F. Hoffmann-la Roche AG	5	$2,252

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Non-Covered Product$2,188

How this compares

$2,252 in reported general payments places this provider in the 30th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia →

Medicare billing

Part B allowed, 2024

$10,406

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OjjaaraMomelotinib Dihydrochloride	23	$608,658
SprycelDasatinib	13	$60,408
EliquisApixaban	13	$7,545
Imatinib Mesylate	11	$1,508
Hydroxyurea	48	$1,061

Paid to pharmacies, not to this prescriber.

Other medical oncology in Atlanta

Nabil SabaAtlanta$225K
Suresh RamalingamAtlanta$75K
Jonathan KaufmanAtlanta$73K
Ragini KudchadkarAtlanta$69K
Nisha JosephAtlanta$50K
Eyal MeiriAtlanta$39K
Erin DunbarAtlanta$35K
Olumide GbolahanAtlanta$32K
Bradley CarthonAtlanta$31K
Joseph MaakaronAtlanta$29K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →